Trials / Unknown
UnknownNCT02711865
Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- Hillel Yaffe Medical Center · Other Government
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main goal of this study is to employ a novel proteomic approach to identify predictive tumor biomarkers that will increase the efficacy of insulin-like growth factor (IGF1R) targeted therapy in epithelial ovarian cancer. It is expected that these predictive biomarkers will be applied to increase the response rate in selected groups of patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IGF1R antibody MK0646 | |
| OTHER | Saline solution |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2019-05-01
- Completion
- 2019-05-01
- First posted
- 2016-03-17
- Last updated
- 2016-03-17
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT02711865. Inclusion in this directory is not an endorsement.